GPR22抗体;GPR22 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: HT29 cells, human normal kidney tissue, Lo2 cells, human normal liver tissue, human fetal brain tissue, Primary antibody: P08701(RNH1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08701(RNH1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P08701(RNH1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The GPR22 (G Protein-Coupled Receptor 22) antibody is a research tool designed to detect and study the GPR22 protein, an orphan receptor belonging to the G protein-coupled receptor (GPCR) superfamily. GPCRs are transmembrane proteins critical for signal transduction, regulating diverse physiological processes. GPR22. first identified through genomic analyses, remains an undercharacterized receptor with no confirmed endogenous ligand, though its sequence homology suggests potential roles in neurological, cardiovascular, or metabolic pathways.

Antibodies targeting GPR22 are typically developed using synthetic peptides or recombinant protein fragments corresponding to specific extracellular or intracellular domains. These antibodies enable researchers to investigate GPR22's expression patterns, subcellular localization, and interaction partners via techniques like Western blotting, immunohistochemistry, or flow cytometry. Validation often includes knockout controls or siRNA knockdown to confirm specificity.

Interest in GPR22 has grown due to its putative involvement in diseases. Studies link its expression to cardiac arrhythmias, obesity-related metabolic disorders, and neuropsychiatric conditions, though mechanistic insights remain limited. The antibody serves as a key reagent in exploring GPR22's pathophysiological relevance and its potential as a therapeutic target. Commercial availability of GPR22 antibodies has facilitated preliminary screenings, yet challenges persist in standardizing reagents due to the receptor's low abundance and tissue-specific expression. Ongoing research aims to elucidate ligand interactions and downstream signaling to unlock its biological significance.